Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
BG Medicine, Inc. (BGMD)
|
Add to portfolio |
|
|
|
| Price: |
$0.00
| | Metrics |
| OS: |
11.3
|
M
| |
-1126
|
% ROE
|
| Market cap: |
$1.1
|
k
| |
|
|
|
Net cash:
|
$1.52
|
M
| |
$0.13
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($56.5)
|
M
| |
|
|
|
EBIT
|
($4.6)
|
M
| |
|
|
| EPS |
($0.64)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 |
| Revenues | 1.6 | 2.8 | 4.1 | 2.8 | 1.6 | 0.8 | 8.5 | 14.6 |
| Revenue growth | -43.8% | -31.6% | 44.7% | 72.3% | 99.5% | -90.4% | -41.8% | 62.3% |
| Cost of goods sold | 0.5 | 1.0 | 1.4 | 1.0 | 0.6 | 0.8 | 8.4 | 13.8 |
| Gross profit | 1.1 | 1.8 | 2.7 | 1.9 | 1.0 | 0.0 | 0.1 | 0.8 |
| Gross margin | 67.8% | 65.7% | 65.9% | 66.0% | 62.1% | 4.0% | 0.7% | 5.2% |
| Selling, general and administrative | | | | | | | 7.5 | 4.5 |
| Sales and marketing | 0.3 | 2.3 | 6.2 | 9.5 | 5.3 | 3.8 | | |
| Research and development | 1.8 | 2.4 | 3.7 | 7.6 | 8.0 | 6.5 | 8.5 | 6.9 |
| General and administrative | 3.6 | 4.5 | 7.1 | 7.6 | 5.2 | 4.3 | | |
| EBITA | -4.6 | -7.3 | -14.3 | -22.6 | -17.4 | -14.6 | -16.0 | -10.6 |
| EBITA margin | -292.0% | -262.1% | -351.1% | -804.4% | -1064.9% | -1783.4% | -188.3% | -72.5% |
| Amortization of intangibles | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | | | |
| EBIT | -4.6 | -7.4 | -14.4 | -22.7 | -17.5 | -14.6 | -16.0 | -10.6 |
| EBIT margin | -295.7% | -264.2% | -352.9% | -807.4% | -1070.1% | -1783.4% | -188.3% | -72.5% |
| Pre-tax income | -5.3 | -8.1 | -15.8 | -23.8 | -17.6 | -17.2 | -16.1 | -15.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 1.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | | 0.0% |
| Net income | -7.0 | -8.1 | -15.8 | -23.8 | -17.7 | -17.2 | -16.1 | 0.0 |
| Net margin | -444.3% | -289.3% | -389.1% | -844.4% | -1083.2% | -2095.5% | -190.1% | -0.1% |
| |
| Diluted EPS | ($0.72) | ($0.99) | ($2.33) | ($1.18) | ($1.00) | ($5.78) | ($5.84) | ($5.52) |
| Shares outstanding (diluted) | 9.6 | 8.2 | 6.8 | 20.2 | 17.6 | 3.0 | 2.8 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|